EGFR and non-small cell lung carcinoma: Diverse kinds of EGFR-TKIs have been approved as the first-line standard therapy for advanced NSCLC with EGFR-sensitive mutations in China, including 1G reversible inhibitors erlotinib, gefitinib and icotinib, 2G irreversible and covalent inhibitors afatinib and dacomitinib, and 3G irreversible ones including osimertinib, almonertinib and furmonertinib.